Metabolic dysfunction-associated steatotic liver disease (MASLD) is under-recognised: Should hepatic elastography be integrated into early risk stratification for people with type 2 diabetes?
- DOI
- 10.1016/j.clinme.2026.100629
- Published
- 2026-07
- Container
- Clinical Medicine
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.clinme.2026.100629,
title = {Metabolic dysfunction-associated steatotic liver disease (MASLD) is under-recognised: Should hepatic elastography be integrated into early risk stratification for people with type 2 diabetes?},
author = {Aftab Ala and Ponnusamy Saravanan},
year = {2026},
journal = {Clinical Medicine},
doi = {10.1016/j.clinme.2026.100629},
url = {https://doi.org/10.1016/j.clinme.2026.100629}
}RIS
TY - JOUR TI - Metabolic dysfunction-associated steatotic liver disease (MASLD) is under-recognised: Should hepatic elastography be integrated into early risk stratification for people with type 2 diabetes? AU - Aftab Ala AU - Ponnusamy Saravanan PY - 2026 JO - Clinical Medicine DO - 10.1016/j.clinme.2026.100629 UR - https://doi.org/10.1016/j.clinme.2026.100629 ER -
APA
Ala, A., & Saravanan, P. (2026). Metabolic dysfunction-associated steatotic liver disease (MASLD) is under-recognised: Should hepatic elastography be integrated into early risk stratification for people with type 2 diabetes?. Clinical Medicine. https://doi.org/10.1016/j.clinme.2026.100629
Source records
- crossref · retrieved 2026-09-25T17:32:29.293Z